News

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

The 2018 Impact of Inflammatory Bowel Disease in Canada Report, and Crohn’s and Colitis Awareness Month

The 2018 Impact of Inflammatory Bowel Disease in Canada Report, and Crohn’s and Colitis Awareness Month

 1 2 3 4 5 6 7 8 9 10 

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest